Gilead Sciences (GILD): 'Acquisition Wanted! - Please Apply Within'

Gild Sciences (GILD) PT Drops to $75 at BMO on Bad Guidance

BMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.

Somaiya comments, "We are maintaining our Market... More

Gilead Sciences (GILD) Pressured on Market Open, Shares Down 10%

Gilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%

Active options: GILD AAPL BAC FB DIS JPM TWTR NVDA AMD NFLX AMZN FCX MU GM AKAM GE PG

Active options: GILD AAPL BAC FB DIS JPM TWTR NVDA AMD NFLX AMZN FCX MU GM AKAM GE PG X BABA

Pre-Open Stock Movers 02/08: (MYGN) (COHR) (MCHP) Higher; (GALE) (USNA) (EYES) Lower (more...)

Today's Pre-Open Movers:

Galena Biopharma, Inc. (NASDAQ: GALE) 38.6% LOWER; announced the pricing of an underwritten public offering of units with anticipated gross proceeds of $17,000,000, before deducting underwriting discounts and commissions and estimated offering expenses payable by Galena. Each unit consists of one full share of its common stock and a warrant to purchase one share of its common stock and is priced at $1.00 per unit. The warrants are immediately exercisable at a price of $1.10 per share of common stock and will expire on the... More

S&P 500 ekes out gain while banks drag on Dow

By Lewis Krauskopf

(Reuters) - The S&P 500 ended slightly higher on Wednesday as investors digested mixed earnings reports, while the Dow Jones Industrial Average slipped as bank stocks weighed.

The Nasdaq gained moderately to close at a record high for a second straight day, lifted by big tech names such as Facebook (NASDAQ: FB) and Apple (NASDAQ: AAPL).

Allergan (NYSE: AGN) shares rose 3.7 percent after the drugmaker's fourth-quarter profit and revenue topped estimates. Gilead Sciences (NASDAQ:... More

Gilead Sciences (GILD) PT Lowered to $75 at RBC Capital

RBC Capital lowered its price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $90.00) while maintaining a Outperform rating.

Analyst Michael Yee comments "GILD reported 2017 guidance well below consensus and expectations on declining volumes (and price). We see $63-67 as a DCF no... More

Needham & Company Remains Sidelined on Gilead Sciences (GILD) Following 4Q

Needham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.

Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by... More

Gilead Sciences (GILD) PT Lowered to $83 at Jefferies

Jefferies lowered its price target on Gilead Sciences (NASDAQ: GILD) to $83.00 (from $93.00) while maintaining a Buy rating.

Analyst Dr. Brian Abrahams comments "Accumulating challenges to HCV franchise finally come to a head, with solid 4Q overshadowed by guidance dramatically lower than consensus. Low... More

Gilead (GILD) PT Drops to $87 at Baird on 2017 Guidance

Baird analyst Brian Skorney maintains Outperform rating, but lowers price target on Gilead Sciences (NASDAQ: GILD) to $87 (from $100), as the company provided fiscal year revenue guidance well below consensus.

Skorney notes, 2017 guidance likely to bottom out stock. We believe investors were expecting... More

Piper Jaffray On Gilead (GILD) - It Stinks But If You Hold Your Nose It's Not That Bad

Piper Jaffray lowered its price target on Gilead Sciences (NASDAQ: GILD) to $95.00 (from $102.00) while maintaining a Overweight rating.

Analyst Dr. Joshua Schimmer comments "It stinks--but if you hold your nose, it's not that bad: Most are frustrated by GILD's "evasive maneuvering" when asked... More

Gilead Sciences (GILD) PT Lowered to $79 at Credit Suisse, Says M&A Is Upside Driver From Here

Credit Suisse lowered its price target on Gilead Sciences (NASDAQ: GILD) to $79.00 (from $93.00) while maintaining a Outperform rating.

Analyst Alethia Young comments "Growth likely through M&A (or deployment of cash) has to be the core of our thesis from here.... More

Welsl Fargo Lowering PT Range On Gilead (GILD)

Wells Fargo maintains Market Perform Gilead Sciences (NASDAQ: GILD)

The analyst is lower the valuation range for GILD from $77-82 to $63-$68, commenting "Medicaid patients could provide stability in 2017, according to GILD. Offsetting, partially, declining HCV product sales is growth of non-HIV... More

Gilead Sciences (GILD) PT Lowered to $77 at Morgan Stanley

Morgan Stanley lowered its price target on Gilead Sciences (NASDAQ: GILD) to $77.00 (from $85.00) while maintaining a Equalweight rating.

Analyst Matt Harrison comments "4Q16 beat, but 2017 rev guide was 15% below cons and 9% below our Street low ests. HCV (-30% vs cons;... More

Citi Downgrades Gilead Sciences (GILD) to Neutral

Citi downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Neutral with a price target of $76.00 (from $87.00).

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $73.13 yesterday.

After-Hours Stock Movers 02/07: (COHR) (MCHP) (JIVE) Higher; (USNA) (DRYS) (ZG) (GILD) Lower (more...)

Today's After-Hours Movers:

USANA Health Sciences (NYSE: USNA) 20.1% LOWER; reported Q4 EPS of $0.87, $0.07 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $252.9 million versus the consensus estimate of $253.52 million. GUIDANCE: USANA Health Sciences sees FY2017 EPS of $3.80-$4.10, versus the consensus of $4.47. USANA Health Sciences sees FY2017 revenue of $1.04-1.07 million, versus the consensus of $1.11 million.

Coherent, Inc. (NASDAQ: COHR) 13.5% HIGHER; reported Q2 Non-GAAP EPS of $2.57, $0.81 better than the analyst estimate of... More

Gilead Sciences (GILD) Raises Quarterly Dividend 10.6% to $0.52; 2.8% Yield

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.52 per share, or $2.08 annualized. This is a 10.6% increase from the prior dividend of $0.47.

The dividend will be payable on March 30, 2017, to stockholders of record on March 16, 2017, with an ex-dividend date of March 14,... More

Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance

Gilead Sciences (NASDAQ: GILD) reported Q4 EPS of $2.70, $0.09 better than the analyst estimate of $2.61. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.15 billion.

Full... More